lucentis

The Food and Drug Administration has not approved Avastin for use in the eye, and using it rather than the alternative, Lucentis, might carry an additional, although slight, safety risk.

美国食品和药品管理局还没有批准阿瓦斯汀用于眼部治疗，使用它来代替雷珠单抗可能会产生额外的安全风险，尽管这一风险也许很轻微。

Medicare could save hundreds of millions of dollars a year if everyone used the cheaper drug, Avastin, instead of the costlier one, Lucentis.

如果每个人都使用更便宜的药物安维汀，而不是更昂贵的雷珠单抗，那么医疗保障每年就可以节省数亿美元。

The medicine is Lucentis, licensed to treat the condition by the European Commission in March.

3月份，欧盟委员会通过了一种名为Lucentis的药物，该药品巳经用于治疗这种病症。

But Lucentis has to be injected into the eye every month or two, a burden for patients and doctors.

使用Lucentis治疗需要每一两个月进行眼部注射，无论对患者还是医生来说，都是一个沉重负担。

The expensive version - Lucentis - is about $2000 per injection, and patients may need a shot every 4 to 6 weeks.

较贵的药物--雷珠单抗注射液（Lucentis）--每注射一次2000美元（约13600元），病患可能每4-6周就需要注射一次。 毫无疑问它的药效良好；实际上，这是第一种针对AMD可以扭转视力下降的有证药物。